AR101728A1 - Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas - Google Patents

Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas

Info

Publication number
AR101728A1
AR101728A1 ARP150102789A ARP150102789A AR101728A1 AR 101728 A1 AR101728 A1 AR 101728A1 AR P150102789 A ARP150102789 A AR P150102789A AR P150102789 A ARP150102789 A AR P150102789A AR 101728 A1 AR101728 A1 AR 101728A1
Authority
AR
Argentina
Prior art keywords
doxylamine
component
active ingredient
piridoxine
metabolites
Prior art date
Application number
ARP150102789A
Other languages
English (en)
Inventor
Gervais Ric
Gallo Michele
St-Onge Jean
Luc - Vranderick Manon
Original Assignee
Duchesnay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duchesnay Inc filed Critical Duchesnay Inc
Publication of AR101728A1 publication Critical patent/AR101728A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de dosificación oral sólida que comprende un núcleo que comprende un componente de doxilamina y un componente de piridoxina revestido con un revestimiento entérico. La forma de dosificación oral sólida comprende además dos revestimientos que contienen ingrediente activo que rodean el revestimiento entérico, los revestimientos que contienen ingrediente activo se separan uno del otro por un revestimiento intermedio, y uno de los dos revestimientos contiene ingrediente activo que comprende un componente de doxilamina y está libre de un componente de piridoxina, y el otro de los dos revestimientos contiene ingrediente activo que comprende un componente de piridoxina y está libre de componente de doxilamina. Usos de la forma de dosificación oral sólida para el alivio de los síntomas de náuseas y vómito, por ejemplo en el caso de náuseas y vómito del embarazo (NVP).
ARP150102789A 2014-08-29 2015-08-31 Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas AR101728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2014/050828 WO2016029290A1 (en) 2014-08-29 2014-08-29 Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Publications (1)

Publication Number Publication Date
AR101728A1 true AR101728A1 (es) 2017-01-11

Family

ID=55398524

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102789A AR101728A1 (es) 2014-08-29 2015-08-31 Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas

Country Status (25)

Country Link
EP (1) EP3185856B1 (es)
JP (1) JP6272561B2 (es)
KR (1) KR101831570B1 (es)
CN (1) CN106794148B (es)
AR (1) AR101728A1 (es)
AU (1) AU2014405049B2 (es)
CA (1) CA2920247C (es)
CY (1) CY1120788T1 (es)
DK (1) DK3185856T3 (es)
EA (1) EA032671B1 (es)
ES (1) ES2674996T3 (es)
FR (1) FR24C1000I1 (es)
HU (1) HUE038969T2 (es)
IL (1) IL250541B (es)
MX (1) MX360662B (es)
MY (1) MY196073A (es)
PH (1) PH12017500282B1 (es)
PL (1) PL3185856T3 (es)
PT (1) PT3185856T (es)
SA (1) SA517380942B1 (es)
SG (1) SG11201701448XA (es)
TR (1) TR201809565T4 (es)
UA (1) UA118711C2 (es)
WO (1) WO2016029290A1 (es)
ZA (1) ZA201701063B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61368B1 (sr) * 2018-09-27 2021-02-26 Inibsa Ginecologia S A Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
PE20260122A1 (es) 2023-05-22 2026-01-16 Italfarmaco Spa Una forma de dosificacion oral de unidades multiples de succinato de doxilamina y clorhidrato de piridoxina sin dioxido de titanio

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
CA2350195C (en) 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
TWI292138B (en) * 2004-03-11 2008-01-01 Mstar Semiconductor Inc Device for adaptively adjusting video's luminance and related method
ME01615B (me) * 2004-11-05 2014-09-20 Boehringer Ingelheim Int Dvoslojna tableta koja sadrži telmisartan i amlodipin
EP2408427A1 (en) * 2009-03-20 2012-01-25 Novartis AG Galenical formulations of a fixed dose combination of valsartan and aliskiren
EP2500016A1 (en) * 2011-03-18 2012-09-19 Laboratorios Del. Dr. Esteve, S.A. Doxylamine resinate complex
CA2761212A1 (en) * 2011-12-07 2013-06-07 Pharmascience Inc. Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing
WO2013123569A1 (en) * 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
MX355912B (es) * 2012-02-22 2018-05-04 Duchesnay Inc Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.

Also Published As

Publication number Publication date
PT3185856T (pt) 2018-10-09
IL250541B (en) 2018-12-31
JP6272561B2 (ja) 2018-01-31
DK3185856T3 (en) 2018-07-30
TR201809565T4 (tr) 2018-07-23
CA2920247A1 (en) 2016-02-29
EP3185856A1 (en) 2017-07-05
MY196073A (en) 2023-03-13
PL3185856T3 (pl) 2018-09-28
PH12017500282A1 (en) 2017-06-28
ZA201701063B (en) 2019-11-27
CA2920247C (en) 2017-01-03
AU2014405049B2 (en) 2017-04-20
HUE038969T2 (hu) 2018-12-28
SG11201701448XA (en) 2017-03-30
AU2014405049A1 (en) 2017-04-06
EP3185856A4 (en) 2017-09-13
SA517380942B1 (ar) 2021-05-16
KR101831570B1 (ko) 2018-02-22
JP2017525731A (ja) 2017-09-07
IL250541A0 (en) 2017-03-30
WO2016029290A1 (en) 2016-03-03
EP3185856B1 (en) 2018-05-23
PH12017500282B1 (en) 2017-06-28
FR24C1000I1 (fr) 2024-02-23
EA032671B1 (ru) 2019-06-28
CN106794148B (zh) 2018-12-21
MX2017002495A (es) 2017-09-13
EA201790477A1 (ru) 2017-07-31
BR112017004190A2 (pt) 2017-12-12
CN106794148A (zh) 2017-05-31
ES2674996T3 (es) 2018-07-05
UA118711C2 (uk) 2019-02-25
CY1120788T1 (el) 2020-05-29
NZ729042A (en) 2021-01-29
MX360662B (es) 2018-11-13
KR20170046163A (ko) 2017-04-28

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
IL254353B (en) Vaporizer capsule for vaporising an active ingredient
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
UY36275A (es) Compuestos aminopirimidinilo
BR112016024631A2 (pt) cápsulas antimicrobianas para conectores médicos
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX356181B (es) Sistemas y bandejas de manejo de fibras y dispositivos de interfaz de red que incorporan tales sistemas y bandejas.
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
MX2018015985A (es) Composiciones, dispositivos y metodos para el tratamiento del trastorno relacionado con el consumo de alcohol.
BR112016024539A8 (pt) Combinador óptico ativo para rede catv
BR112018074655A2 (pt) formulação injetável de fosnetupitant e método de fabricação de uma formulação
CR20180089A (es) Compuestos útiles para inhibir a ror-gamma-t
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
AR101728A1 (es) Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas
BR112018070615A2 (pt) formulação em grânulos contendo cloridrato de cariprazina para administração oral.
DOS2020000142S (es) Embalaje de almacenamiento (para fármacos)
MX384637B (es) Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas.
MX2020004202A (es) Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas.
CL2018002461A1 (es) Composiciones farmacéuticas disuasivas del abuso.

Legal Events

Date Code Title Description
FC Refusal